Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Hilary A. Vaughan"'
Autor:
Hui K Gan, Anne Zhao, Paul Mitchell, Vaios Karanikas, Ian F. C. McKenzie, Peter Kyriakou, Kate Hamilton, Shane White, Vasso Apostolopoulos, Bruce E. Loveland, Pei-Xiang Xing, Hilary A. Vaughan, Geoffrey A. Pietersz
Publikováno v:
Clinical Cancer Research. 12:869-877
Purpose: Tumor antigen-loaded dendritic cells show promise for cancer immunotherapy. This phase I study evaluated immunization with autologous dendritic cells pulsed with mannan-MUC1 fusion protein (MFP) to treat patients with advanced malignancy. Ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72214a310346efbc76ea3d6bf3e8c0f1
https://doi.org/10.1158/1078-0432.ccr-05-1574
https://doi.org/10.1158/1078-0432.ccr-05-1574
Autor:
Ian D. Davis, Achim A. Jungbluth, Judy Browning, Jonathan Cebon, Sue Sturrock, Philip Parente, Yao-Tseng Chen, Suzanne Svobodova, Elisabeth Stockert, Fiona St. Clair, Lloyd J. Old, Hilary A. Vaughan, Duncan MacGregor
Publikováno v:
Clinical Cancer Research. 10:8396-8404
Purpose: NY-ESO-1 and LAGE-1 are homologous cancer-testis antigens, which are expressed in many different cancers. It is essential to type tumors accurately to assess patient suitability for clinical trials which target these. This study evaluates ty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e849bf242eb0d89f89804d78b2def18d
https://doi.org/10.1158/1078-0432.ccr-04-0809
https://doi.org/10.1158/1078-0432.ccr-04-0809
Autor:
Hilary A. Vaughan, Ian F. C. McKenzie, Vaios Karanikas, Deborah W.M Ho, Mauro S. Sandrin, Geoffrey A. Pietersz
Publikováno v:
Vaccine. 18:3297-3309
Mice immunised with human epithelial mucin MUC1 coupled to oxidised mannan produce MUC1 specific MHC Class 1 restricted CD8(+) cytotoxic T cells and are completely protected from the development of MUC1(+) tumours; such therapy may be applicable to h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70da1074d8b0e179c6f44295bad8dab8
https://doi.org/10.1016/s0264-410x(00)00143-2
https://doi.org/10.1016/s0264-410x(00)00143-2
Autor:
Jonathan Cebon, Ian D. Davis, Peter Gibbs, A M Hutchins, Hilary A. Vaughan, Mervyn J. Silvapulle, K T Dorian
Publikováno v:
Melanoma Research. 10:259-264
MAGE proteins have been identified as potential specific targets for cancer vaccination. Although MAGE-6 and MAGE-12 were originally identified in malignant melanoma there are no studies reporting the frequency of expression of these antigens in this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::618355720c852cdeed39f5e82361f0f0
https://doi.org/10.1097/00008390-200010030-00008
https://doi.org/10.1097/00008390-200010030-00008
Autor:
Deborah W.M Ho, Le Ann Hwang, Hilary A. Vaughan, Julian M Pearson, Chin-Swee Ong, Vaios Karanikas, Geoffrey A. Pietersz, Ian F. C. McKenzie
Publikováno v:
Vaccine. 17:2740-2752
Mice immunised with oxidised mannan conjugated to the human mucin 1 (MUC1), produce MHC Class 1 restricted CD8+ cytotoxic T-cells which eradicate MUC1 + tumours, indicating potential for the immunotherapy of MUC1 + cancers in humans. We now describe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d2ba0b2556a44c6fed71f32fb67d3e9
https://doi.org/10.1016/s0264-410x(98)00493-9
https://doi.org/10.1016/s0264-410x(98)00493-9
Autor:
Julian M Pearson, Vasso Apostolopoulos, R. Broadbent, Vaios Karanikas, Ian F. C. McKenzie, Brian D. Tait, Hilary A. Vaughan, G. Thynne, Gary P. Jamieson, Pei Xiang Xing, C.-S. Ong, L.-A. Hwang, Geoffrey A. Pietersz
Publikováno v:
Journal of Clinical Investigation. 100:2783-2792
Mucin 1 (MUC1) is a large complex glycoprotein that is highly expressed in breast cancer, and as such could be a target for immunotherapy. In mice, human MUC1 is highly immunogenic, particularly when conjugated to mannan, where a high frequency of CD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6910b174e558ec5f18dd8738480f6ca2
https://doi.org/10.1172/jci119825
https://doi.org/10.1172/jci119825
Publikováno v:
Glycoconjugate Journal. 14:97-105
We have recently demonstrated that both antibodies to Gal alpha(1,3)Gal, and the Gal alpha(1,3)Gal binding lectin (IB4), bind a synthetic peptide (DAHWESWL), there being a similar recognition of carbohydrate and peptide structures. We now report that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d04acf1118ab4c24d33eeb1871b4187
https://doi.org/10.1023/a:1018521217276
https://doi.org/10.1023/a:1018521217276
Autor:
James R. Goldenring, Hilary D. Vaughan, Jennifer Navarre, Wendy Hawkins, Jenetta Smith, Patricia L. Cameron
Publikováno v:
American Journal of Physiology-Gastrointestinal and Liver Physiology. 270:G515-G525
Rab proteins are involved in many aspects of dynamic vesicle processing within eukaryotic cells. We have previously identified Rab11 in gastric parietal cell tubulovesicle membranes. We have produced a monoclonal antibody that is specific for Rab11.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d0edd2a37984bc94e2d6c0f96d2b3dc
https://doi.org/10.1152/ajpgi.1996.270.3.g515
https://doi.org/10.1152/ajpgi.1996.270.3.g515
Autor:
Kevin R. Oldenburg, Julie D. Atkin, Ian F. C. McKenzie, Mark A. Gallop, Mauro S. Sandrin, Hilary A. Vaughan
Publikováno v:
Macquarie University
Strategies are now being designed to overcome the hyperacute rejection of vascularized pig xenografts by human natural anti-Galα(1,3)Gal antibodies. We now demonstrate that a synthetic octapeptide, Gal pep 1 (DAHWESWL), isolated from a peptide epito
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4f6897b7e78cf6f48e5830be42f4d7f
https://doi.org/10.1111/j.1399-3089.1996.tb00114.x
https://doi.org/10.1111/j.1399-3089.1996.tb00114.x
Publikováno v:
Transplantation Reviews. 8:134-149
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::285b0a1dde051de3d367a630897acce6
https://doi.org/10.1016/s0955-470x(05)80033-3
https://doi.org/10.1016/s0955-470x(05)80033-3